MedPath

UVAX BIO, LLC

🇺🇸United States
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

1

Active:0
Completed:1

Trial Phases

1 Phases

Early Phase 1:1

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials

Early Phase 1
1 (100.0%)

Study to Evaluate the Safety and Immunogenicity of an HIV-1 Vaccine Regimen of Adjuvanted UVAX-1107 Followed by Adjuvanted UVAX-1107 or Adjuvanted UVAX-1197 in Healthy Subjects Aged 25-55 Years.

Early Phase 1
Completed
Conditions
HIV Infections
AIDS/HIV - RelatedDisease Associated With AIDS
Vaccine-Preventable Diseases
Interventions
First Posted Date
2024-08-07
Last Posted Date
2025-05-23
Lead Sponsor
Uvax Bio LLC
Target Recruit Count
34
Registration Number
NCT06541093
Locations
🇦🇺

Nucleus Network Melbourne, Melbourne, Victoria, Australia

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.